US20040122000A1
(en)
*
|
1981-01-07 |
2004-06-24 |
Vertex Pharmaceuticals Incorporated. |
Inhibitors of aspartyl protease
|
UA59384C2
(uk)
*
|
1996-12-20 |
2003-09-15 |
Пфайзер, Інк. |
Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
|
US6436989B1
(en)
*
|
1997-12-24 |
2002-08-20 |
Vertex Pharmaceuticals, Incorporated |
Prodrugs of aspartyl protease inhibitors
|
US6686366B1
(en)
|
1998-06-02 |
2004-02-03 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6878716B1
(en)
|
1998-06-02 |
2005-04-12 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptor and uses thereof
|
MXPA00011889A
(es)
|
1998-06-02 |
2003-04-25 |
Osi Pharm Inc |
Composiciones de pirrolo (2,3d) piridina y su uso.
|
GB9815567D0
(en)
*
|
1998-07-18 |
1998-09-16 |
Glaxo Group Ltd |
Antiviral compound
|
AU6329599A
(en)
*
|
1998-09-28 |
2000-04-17 |
Glaxo Group Limited |
Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
|
GB9914821D0
(en)
*
|
1999-06-24 |
1999-08-25 |
Glaxo Group Ltd |
Compounds
|
US6664252B2
(en)
|
1999-12-02 |
2003-12-16 |
Osi Pharmaceuticals, Inc. |
4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
|
US6680322B2
(en)
|
1999-12-02 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US7160890B2
(en)
|
1999-12-02 |
2007-01-09 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6680324B2
(en)
|
2000-12-01 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US6673802B2
(en)
|
2000-12-01 |
2004-01-06 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
ES2275866T3
(es)
|
2001-02-14 |
2007-06-16 |
Tibotec Pharmaceuticals Ltd. |
2-(aminosustituido)-benzotiazol-sulfonamidas de amplio esprecto inhibidoras de la proteasa de vih.
|
AP1544A
(en)
|
2001-04-09 |
2006-01-12 |
Tibotec Pharm Ltd |
Broadspectrum 2- (substituted-amino) -benzoxazole sulfonamide HIV protease inhibitors.
|
EA009590B1
(ru)
|
2001-05-11 |
2008-02-28 |
Тиботек Фармасьютикалз Лтд. |
2-аминобензоксазолсульфонамидные ингибиторы вич-протеазы широкого спектра
|
US7576084B2
(en)
*
|
2001-10-12 |
2009-08-18 |
Choongwae Pharma Corporation |
Reverse-turn mimetics and method relating thereto
|
EP1450811B1
(en)
|
2001-11-30 |
2009-10-21 |
OSI Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 and A3 receptors and uses thereof
|
TWI286476B
(en)
*
|
2001-12-12 |
2007-09-11 |
Tibotec Pharm Ltd |
Combination of cytochrome P450 dependent protease inhibitors
|
CN1620294A
(zh)
|
2001-12-20 |
2005-05-25 |
Osi药物公司 |
嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
|
CN1816551A
(zh)
|
2001-12-20 |
2006-08-09 |
Osi药物公司 |
吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
|
JP4578101B2
(ja)
|
2001-12-21 |
2010-11-10 |
テイボテク・フアーマシユーチカルズ・リミテツド |
幅広いスペクトルのhivプロテアーゼ阻害剤である複素環置換フェニル含有スルホンアミド
|
MY142238A
(en)
|
2002-03-12 |
2010-11-15 |
Tibotec Pharm Ltd |
Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
|
US7157489B2
(en)
*
|
2002-03-12 |
2007-01-02 |
The Board Of Trustees Of The University Of Illinois |
HIV protease inhibitors
|
EA200401437A1
(ru)
*
|
2002-04-26 |
2005-04-28 |
Джилид Сайэнс, Инк. |
Ненуклеозидные ингибиторы обратной транскриптазы для лечения вич инфекции, способ их получения (варианты), способ увеличения периода полупревращения ненуклеозидного соединения, обладающего активностью против ретровирусов, и способ получения фармацевтической композиции, обладающей специфичностью к лейкоцитам
|
ATE371652T1
(de)
|
2002-05-17 |
2007-09-15 |
Tibotec Pharm Ltd |
Substituierte benzisoxazolsulfonamide mit breitbändiger hiv-protease hemmender wirkung
|
JP4681296B2
(ja)
|
2002-08-14 |
2011-05-11 |
テイボテク・フアーマシユーチカルズ・リミテツド |
スペクトルの広い置換オキシインドールスルホンアミドhivプロテアーゼ阻害剤
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
CA2425031A1
(en)
*
|
2003-04-01 |
2004-10-01 |
Smithkline Beecham Corporation |
Pharmaceutical compositions
|
US7432261B2
(en)
|
2003-04-25 |
2008-10-07 |
Gilead Sciences, Inc. |
Anti-inflammatory phosphonate compounds
|
JP2006524710A
(ja)
|
2003-04-25 |
2006-11-02 |
ギリアード サイエンシーズ, インコーポレイテッド |
キナーゼインヒビターホスホネート抱合体
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
WO2004096285A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Anti-infective phosphonate conjugates
|
WO2004096287A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
DK1628685T3
(da)
|
2003-04-25 |
2011-03-21 |
Gilead Sciences Inc |
Antivirale phosphonatanaloge
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
AU2004259659B2
(en)
|
2003-07-09 |
2011-11-03 |
Paratek Pharmaceuticals, Inc. |
Substituted tetracycline compounds
|
CA2531732C
(en)
*
|
2003-07-09 |
2012-04-10 |
Paratek Pharmaceuticals, Inc. |
Prodrugs of 9-aminomethyl tetracycline compounds
|
US20050119163A1
(en)
*
|
2003-09-18 |
2005-06-02 |
The Government Of The United States Of America, As Represented By The Secretary, |
SH2 domain binding inhibitors
|
WO2005044279A1
(en)
|
2003-10-24 |
2005-05-19 |
Gilead Sciences, Inc. |
Purine nucleoside phosphonate conjugates
|
WO2005044308A1
(en)
|
2003-10-24 |
2005-05-19 |
Gilead Sciences, Inc. |
Phosphonate analogs of antimetabolites
|
US7834043B2
(en)
*
|
2003-12-11 |
2010-11-16 |
Abbott Laboratories |
HIV protease inhibiting compounds
|
US20050131042A1
(en)
*
|
2003-12-11 |
2005-06-16 |
Flentge Charles A. |
HIV protease inhibiting compounds
|
US8193227B2
(en)
|
2003-12-11 |
2012-06-05 |
Abbott Laboratories |
HIV protease inhibiting compounds
|
JP5020638B2
(ja)
*
|
2003-12-15 |
2012-09-05 |
シェーリング コーポレイション |
複素環式アスパルチルプロテアーゼインヒビター
|
MXPA06007017A
(es)
|
2003-12-18 |
2006-08-31 |
Janssen Pharmaceutica Nv |
Derivados de pirido y pirimidopirimidina como agentes antiproliferativos.
|
US20080287471A1
(en)
|
2003-12-22 |
2008-11-20 |
Maria Fardis |
4'-Substituted Carbovir And Abacavir-Derivatives As Well As Related Compounds With Hiv And Hcv Antiviral Activity
|
EP2336138A3
(en)
*
|
2004-07-06 |
2011-11-16 |
Abbott Laboratories |
Prodrugs of HIV protease inhibitors
|
HUE043207T2
(hu)
|
2004-07-27 |
2019-08-28 |
Gilead Sciences Inc |
HIV-gátló vegyületek foszfonát analógjai
|
US7388008B2
(en)
*
|
2004-08-02 |
2008-06-17 |
Ambrilia Biopharma Inc. |
Lysine based compounds
|
JP4579970B2
(ja)
*
|
2004-08-02 |
2010-11-10 |
アンブリリア・バイオファーマ・インコーポレーテッド |
リシンをベースにした化合物類
|
WO2006024490A2
(en)
|
2004-08-30 |
2006-03-09 |
Interstitial Therapeutics |
Methods and compositions for the treatment of cell proliferation
|
CA2588517A1
(en)
|
2004-12-01 |
2006-06-08 |
Devgen N.V. |
5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family
|
NI200700147A
(es)
|
2004-12-08 |
2019-05-10 |
Janssen Pharmaceutica Nv |
Derivados de quinazolina inhibidores de cinasas dirigidos a multip
|
JP4326575B2
(ja)
|
2004-12-17 |
2009-09-09 |
デブゲン・エヌ・ブイ |
殺線虫性組成物
|
ATE451381T1
(de)
*
|
2005-01-19 |
2009-12-15 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
WO2006104646A1
(en)
*
|
2005-03-11 |
2006-10-05 |
Smithkline Beecham Corporation |
Hiv protease inhibitors
|
AR053845A1
(es)
|
2005-04-15 |
2007-05-23 |
Tibotec Pharm Ltd |
5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
|
ES2539527T3
(es)
|
2005-04-27 |
2015-07-01 |
Taimed Biologics, Inc. |
Método para mejorar la farmacocinética de los inhibidores de las proteasas y de los precursores de los inhibidores de las proteasas
|
WO2007045496A1
(en)
|
2005-10-21 |
2007-04-26 |
Universiteit Antwerpen |
Novel urokinase inhibitors
|
TWI385173B
(zh)
|
2005-11-28 |
2013-02-11 |
Tibotec Pharm Ltd |
作為hiv蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物
|
TWI432438B
(zh)
|
2005-11-28 |
2014-04-01 |
Tibotec Pharm Ltd |
作為hiv蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物及衍生物
|
CN101506236B
(zh)
|
2005-11-30 |
2012-12-12 |
雅培制药有限公司 |
抗淀粉样β蛋白的单克隆抗体及其用途
|
BRPI0619249A2
(pt)
|
2005-11-30 |
2011-09-20 |
Abbott Lab |
anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
|
AU2006319716B2
(en)
*
|
2005-11-30 |
2012-02-02 |
Taimed Biologics, Inc. |
Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
|
JP4644287B2
(ja)
*
|
2005-12-27 |
2011-03-02 |
大塚製薬株式会社 |
水溶性ベンゾアゼピン化合物及び医薬組成物
|
WO2008006884A2
(en)
|
2006-07-13 |
2008-01-17 |
Janssen Pharmaceutica N.V. |
Mtki quinazoline derivatives
|
CA2858907A1
(en)
|
2006-09-08 |
2008-03-13 |
Bayer Schering Pharma Aktiengesellschaft |
Compounds and methods for 18f labeled agents
|
JP5401652B2
(ja)
|
2006-09-21 |
2014-01-29 |
タイメッド バイオロジクス インコーポレイテッド |
プロテアーゼ阻害剤
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP2486928A1
(en)
|
2007-02-27 |
2012-08-15 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
AU2008226823B2
(en)
|
2007-03-12 |
2014-03-13 |
Nektar Therapeutics |
Oligomer-protease inhibitor conjugates
|
DK2185562T3
(en)
|
2007-07-27 |
2016-02-22 |
Janssen Pharmaceutica Nv |
PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
|
EP2053033A1
(en)
|
2007-10-26 |
2009-04-29 |
Bayer Schering Pharma AG |
Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
|
EP2100900A1
(en)
|
2008-03-07 |
2009-09-16 |
Universitätsspital Basel |
Bombesin analog peptide antagonist conjugates
|
US8318929B2
(en)
|
2008-03-10 |
2012-11-27 |
Janssen Pharmaceutica Nv |
4-aryl-2-anilino-pyrimidines
|
US9095620B2
(en)
*
|
2008-03-12 |
2015-08-04 |
Nektar Therapeutics |
Reagents
|
EP2116236A1
(en)
|
2008-04-21 |
2009-11-11 |
Université de Mons-Hainaut |
Bisbenzamidine derivatives for use as antioxidant
|
US20100093667A1
(en)
|
2008-07-08 |
2010-04-15 |
Gilead Sciences, Inc. |
Salts of hiv inhibitor compounds
|
EP2364314B1
(en)
|
2008-12-09 |
2014-03-12 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
US20120135965A1
(en)
*
|
2009-05-20 |
2012-05-31 |
Ranbaxy Laboratories Limited |
Amorphous fosamprenavir calcium
|
EP2440249A2
(en)
|
2009-06-12 |
2012-04-18 |
Nektar Therapeutics |
Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
|
CA2774483C
(en)
|
2009-09-16 |
2014-11-18 |
Ranbaxy Laboratories Limited |
Process for the preparation of fosamprenavir calcium
|
WO2011061590A1
(en)
|
2009-11-17 |
2011-05-26 |
Hetero Research Foundation |
Novel carboxamide derivatives as hiv inhibitors
|
EP2501431B1
(en)
|
2009-11-19 |
2020-01-08 |
Wellinq Medical B.V. |
Narrow profile composition-releasing expandable medical balloon catheter
|
EP2507250A1
(en)
|
2010-01-07 |
2012-10-10 |
Pliva Hrvastka D.O.O. |
Solid state forms of fosamprenavir calcium salt and process for preparation thereof
|
AP3551A
(en)
|
2010-01-27 |
2016-01-18 |
Viiv Healthcare Co |
Antiviral therapy
|
US20110223131A1
(en)
|
2010-02-24 |
2011-09-15 |
Gilead Sciences, Inc. |
Antiviral compounds
|
US20110224443A1
(en)
*
|
2010-03-15 |
2011-09-15 |
Venkata Naga Brahmeshwara Rao Mandava |
Preparation of fosamprenavir calcium
|
WO2011114212A1
(en)
|
2010-03-19 |
2011-09-22 |
Lupin Limited |
Ammonium, calcium and tris salts of fosamprenavir
|
MX360403B
(es)
|
2010-04-15 |
2018-10-31 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
WO2011141515A1
(en)
|
2010-05-14 |
2011-11-17 |
Bayer Pharma Aktiengesellschaft |
Diagnostic agents for amyloid beta imaging
|
WO2011158259A1
(en)
|
2010-06-18 |
2011-12-22 |
Matrix Laboratories Ltd |
Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts thereof
|
US8785648B1
(en)
|
2010-08-10 |
2014-07-22 |
The Regents Of The University Of California |
PKC-epsilon inhibitors
|
JP6147665B2
(ja)
|
2010-08-14 |
2017-06-14 |
アッヴィ・インコーポレイテッド |
アミロイドベータ結合タンパク質
|
WO2012032389A2
(en)
|
2010-09-10 |
2012-03-15 |
Lupin Limited |
Process for preparation of substantially pure fosamprenavir calcium and its intermediates
|
GB201019043D0
(en)
|
2010-11-10 |
2010-12-22 |
Protea Biopharma N V |
Use of 2',5'-oligoadenylate derivative compounds
|
WO2012085625A1
(en)
|
2010-12-21 |
2012-06-28 |
Lupin Limited |
Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
|
JP2014513044A
(ja)
*
|
2011-02-10 |
2014-05-29 |
マイラン ラボラトリーズ リミテッド |
ホスアンプレナビルカルシウム結晶およびその調製方法
|
AU2012272970A1
(en)
|
2011-06-21 |
2014-02-06 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
US9309213B2
(en)
|
2011-07-11 |
2016-04-12 |
Purdue Research Foundation |
C-3 substituted bicyclooctane based HIV protease inhibitors
|
WO2013011485A1
(en)
|
2011-07-20 |
2013-01-24 |
Ranbaxy Laboratories Limited |
Process for the preparation of sulfonamides useful as retroviral protease inhibitors
|
US9233943B2
(en)
|
2012-01-10 |
2016-01-12 |
Council Of Scientific & Industrial Research |
Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
EP2700396A3
(en)
|
2012-06-20 |
2015-04-29 |
Sylphar Nv |
Strip for the delivery of oral care compositions
|
WO2014059034A2
(en)
|
2012-10-09 |
2014-04-17 |
President And Fellows Of Harvard College |
Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
|
US9227990B2
(en)
|
2012-10-29 |
2016-01-05 |
Cipla Limited |
Antiviral phosphonate analogues and process for preparation thereof
|
LT2929031T
(lt)
|
2012-12-05 |
2018-02-12 |
Alnylam Pharmaceuticals, Inc. |
Pcsk9 irna kompozicijos ir jų naudojimo būdai
|
KR102605775B1
(ko)
|
2013-03-14 |
2023-11-29 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 C5 iRNA 조성물 및 그 이용 방법
|
KR102463973B1
(ko)
|
2013-05-22 |
2022-11-07 |
알닐람 파마슈티칼스 인코포레이티드 |
SERPINA1 iRNA 조성물 및 이의 사용 방법
|
SG11201510565TA
(en)
|
2013-05-22 |
2016-01-28 |
Alnylam Pharmaceuticals Inc |
Tmprss6 irna compositions and methods of use thereof
|
IL282401B
(en)
|
2013-12-12 |
2022-08-01 |
Alnylam Pharmaceuticals Inc |
Complementary component irna compositions and methods for using them
|
CN113057959A
(zh)
|
2014-02-11 |
2021-07-02 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
JP6811094B2
(ja)
|
2014-05-22 |
2021-01-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アンジオテンシノーゲン(AGT)iRNA組成物およびその使用
|
WO2016003450A1
(en)
|
2014-07-01 |
2016-01-07 |
The Regents Of The University Of California |
Pkc-epsilon inhibitors
|
WO2016001907A1
(en)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
|
NZ728072A
(en)
|
2014-07-11 |
2018-06-29 |
Gilead Sciences Inc |
Modulators of toll-like receptors for the treatment of hiv
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
WO2016069955A1
(en)
|
2014-10-29 |
2016-05-06 |
Wisconsin Alumni Research Foundation |
Boronic acid inhibitors of hiv protease
|
EP3904519A1
(en)
|
2014-10-30 |
2021-11-03 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
EP3221451A1
(en)
|
2014-11-17 |
2017-09-27 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
WO2016083490A1
(en)
|
2014-11-27 |
2016-06-02 |
Remynd Nv |
Compounds for the treatment of amyloid-associated diseases
|
EP3256587A2
(en)
|
2015-02-13 |
2017-12-20 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
CA2982450A1
(en)
|
2015-04-13 |
2016-10-20 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
DK3288637T3
(da)
|
2015-04-28 |
2022-10-17 |
Newsouth Innovations Pty Ltd |
Målretning af nad+ til behandling af kemoterapi- og radioterapi-induceret, kognitiv funktionsnedsættelse, neuropatier og inaktivitet
|
KR20180002688A
(ko)
|
2015-05-06 |
2018-01-08 |
알닐람 파마슈티칼스 인코포레이티드 |
인자 XII(하게만 인자)(F12), 칼리크레인 B, 혈장(플레처 인자) 1(KLKB1) 및 키니노겐 1(KNG1) iRNA 조성물 및 그의 이용 방법
|
EP3310918B1
(en)
|
2015-06-18 |
2020-08-05 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
EP3350328A1
(en)
|
2015-09-14 |
2018-07-25 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
EP3349757A1
(en)
|
2015-09-15 |
2018-07-25 |
Gilead Sciences, Inc. |
Modulators of toll-like recptors for the treatment of hiv
|
EP3386518A1
(en)
|
2015-12-07 |
2018-10-17 |
Genzyme Corporation |
Methods and compositions for treating a serpinc1-associated disorder
|
WO2017100542A1
(en)
|
2015-12-10 |
2017-06-15 |
Alnylam Pharmaceuticals, Inc. |
Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
|
US20190256845A1
(en)
|
2016-06-10 |
2019-08-22 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
WO2018112320A1
(en)
|
2016-12-16 |
2018-06-21 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
WO2018206760A1
(en)
|
2017-05-11 |
2018-11-15 |
Remynd N.V. |
Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders
|
JP7384783B2
(ja)
|
2017-07-21 |
2023-11-21 |
ヴィーブ ヘルスケア カンパニー |
Hiv感染症及びaidsを治療するためのレジメン
|
US10851125B2
(en)
|
2017-08-01 |
2020-12-01 |
Gilead Sciences, Inc. |
Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate
|
US11866701B2
(en)
|
2017-11-01 |
2024-01-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
MX2021001056A
(es)
|
2018-08-13 |
2021-04-12 |
Alnylam Pharmaceuticals Inc |
Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.
|
WO2020150431A1
(en)
|
2019-01-16 |
2020-07-23 |
Genzyme Corporation |
Serpinc1 irna compositions and methods of use thereof
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
US20230130598A1
(en)
|
2020-02-24 |
2023-04-27 |
Katholieke Universiteit Leuven |
Pyrrolopyridine and imidazopyridine antiviral compounds
|
US20230218644A1
(en)
|
2020-04-16 |
2023-07-13 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
JP2024500543A
(ja)
|
2020-12-22 |
2024-01-09 |
ルクセンブルク インスティテュート オブ ヘルス(エルアイエイチ) |
がん及び循環器疾患の処置のための選択的ackr3調節物質としてのコノリジンアナログ
|
WO2022184898A1
(en)
|
2021-03-04 |
2022-09-09 |
Universiteit Antwerpen |
Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer
|
WO2022253785A2
(en)
|
2021-05-31 |
2022-12-08 |
Universität Heidelberg |
Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof
|
WO2023021132A1
(en)
|
2021-08-18 |
2023-02-23 |
Katholieke Universiteit Leuven |
6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues
|
WO2023046900A1
(en)
|
2021-09-23 |
2023-03-30 |
Katholieke Universiteit Leuven |
Ribonucleoside analogues against -sars-cov-2
|
WO2023241799A1
(en)
|
2022-06-15 |
2023-12-21 |
Université Libre de Bruxelles |
Flavanols for use in the treatment of retroviral infections
|
WO2024062043A1
(en)
|
2022-09-21 |
2024-03-28 |
Universiteit Antwerpen |
Substituted phenothiazines as ferroptosis inhibitors
|